The invention relates to the field of intravascular catheters, and more particularly to a balloon catheter or other catheter components, such as a guidewire enclosure and catheter tubing, that would benefit from the properties of the materials disclosed herein.
In percutaneous transluminal coronary angioplasty (PTCA) procedures, a guiding catheter is advanced until the distal tip of the guiding catheter is seated in the ostium of a desired coronary artery. A guidewire, positioned within an inner lumen of an dilatation catheter, is first advanced out of the distal end of the guiding catheter into the patient's coronary artery until the distal end of the guidewire crosses a lesion to be dilated. Then the dilatation catheter having an inflatable balloon on the distal portion thereof is advanced into the patient's coronary anatomy, over the previously introduced guidewire, until the balloon of the dilatation catheter is properly positioned across the lesion. Once properly positioned, the dilatation balloon is inflated with liquid one or more times to a predetermined size at relatively high pressures (e.g. greater than 8 atmospheres) so that the stenosis is compressed against the arterial wall and the wall expanded to open up the passageway. Generally, the inflated diameter of the balloon is approximately the same diameter as the native diameter of the body lumen being dilated so as to complete the dilatation but not overexpand the artery wall. The rate of expansion of the balloon for a given pressure is an important consideration in the design of the dilation catheter, as greater than anticipated expansion of the balloon against the vessel wall can cause trauma to the vessel wall. After the balloon is finally deflated, blood flow resumes through the dilated artery and the dilatation catheter can be removed from the patient's artery.
In such angioplasty procedures, there may be restenosis of the artery, i.e. reformation of the arterial blockage, which necessitates either another angioplasty procedure, or some other method of repairing or strengthening the dilated area. To reduce the restenosis rate and to strengthen the dilated area, physicians frequently implant an intravascular prosthesis, generally called a stent, inside the artery at the site of the lesion. Stents may also be used to repair vessels having an intimal flap or dissection or to generally strengthen a weakened section of a vessel. Stents are usually delivered to a desired location within a coronary artery in a contracted condition on a balloon of a catheter which is similar in many respects to a balloon angioplasty catheter, and expanded to a larger diameter by expansion of the balloon. The balloon is deflated to remove the catheter and the stent left in place within the artery at the site of the dilated lesion.
In the design of catheter balloons and catheter tubing, material characteristics such as strength, flexibility and compliance must be tailored to provide optimal performance for a particular application. Angioplasty balloons and catheter tubing preferably have high strength for inflation at relatively high pressure, and high flexibility and softness for improved ability to track the tortuous anatomy. The balloon compliance, for example, is chosen so that the balloon will have a desired amount of expansion during inflation. Compliant balloons, for example balloons made from materials such as polyethylene, exhibit substantial stretching upon the application of tensile force. Noncompliant balloons, for example balloons made from materials such as PET, exhibit relatively little stretching during inflation, and therefore provide controlled radial growth in response to an increase in inflation pressure within the working pressure range. However, noncompliant balloons generally have relatively low flexibility and softness, making it more difficult to maneuver through various body lumens. Heretofore the art has lacked an optimum combination of strength, flexibility, and compliance, and particularly a low to non-compliant balloon with high flexibility and softness for enhanced trackability. Semi-compliant balloons made from semi-crystalline nylon 11, nylon 12, and copolymers of these nylons, such as poly ether block amide (for example, Pebax from Arkema) address these shortcomings and provide low distensibility and good flexibility, thus being used in many balloon dilatation catheters and stem delivery system.
For ease of thermal bonding to afore mentioned semi-compliant balloons, it is also preferred that the shaft of the balloon dilatation catheters and stent delivery system are also derived from same materials. Many balloon dilatation catheters and stent delivery systems therefore use shafts derived from these materials. The relative hardness and flexibility of the catheter tubing is also a constant compromise between the need for an agile tubing that can navigate the various body lumens, while having enough stiffness to be able to be pushed from a proximal end outside the body through the patient's vascular tract. A tubing that is relatively stiff will transmit proximal force more efficiently to the distal end, giving the practitioner more control over the location and position of the catheter balloon. However, stiffer tubing makes it much more difficult to bend or track curvatures in the body, leading to the paradox of the need for stiffer yet more flexible tubing. Moreover, stiffer materials when used to make catheter shafts have a higher tendency to kink, making it more difficult to control or push. Therefore, it is desirable to be able to increase stiffness and thus pushability by incorporating nylons having higher stiffness than semi-crystalline nylons having been used thus far. Some amorphous nylons offer desired higher stiffness than semi-crystalline nylons. However, the higher stiffness amorphous nylons are more susceptible to damage from solvents, such as isopropyl alcohol, used in the manufacturing, cleaning processes, and during clinical use. The present invention is directed to address this issue.
The softness and flexibility of a balloon or catheter tubing is a function of the flexural modulus of the polymeric material of the balloon, so that a balloon or tubing material having a higher Shore D durometer hardness, which yields a stronger and stiffer balloon or catheter tubing, has a higher flexural modulus. Conversely, a balloon or catheter tubing material having a lower Shore D durometer hardness, which thus provides a soft and flexible balloon or tubing, has a lower flexural modulus. The present invention is directed to a catheter tubing formed with a combination of at least two polyamides, a high durometer hardness material and a lower durometer hardness material.
The tubing can be made from a blend of the two polyamides, or a co-extrusion of the two polyamides with an inner layer and an outer layer. The first inner polyamide has a Shore D durometer hardness of greater than 78 D, more preferably Shore D durometer hardness of greater than 80 D, and can be preferably selected from various transparent amorphous nylons having segment such as an aliphatic segment, an aromatic segment, or a cycloaliphatic segment. The second outer polyamide has a lower durometer hardness than the first polyamide, and preferably less than 76 D, and preferably a block copolymer of nylon and polytetramethylene oxide (i.e. a copolyamide), or Pebax. The second outer polyamide is preferably semi-crystalline polyamide, thus providing enhanced resistance to solvents, such as isopropyl alcohol, used in the manufacturing, cleaning processes, and during clinical use. Both inner and outer polyamides preferably have the same amide block or segment, e.g. nylon 12, nylon 11, or nylon 6,6.
The preferred high hardness material is a nylon referred to as transparent amorphous nylon. The transparent amorphous nylon preferably has either an aliphatic segment, an aromatic segment, or a cycloaliphatic segment.
The catheter tubing of the invention may be formed by coextruding a tubular product formed from the two polymeric components to create a tubing having an outer layer and an inner layer of the two materials.
Various designs for balloon catheters well known in the art may be used in the catheter system of the invention. For example, conventional over-the-wire balloon catheters for angioplasty or stent delivery usually include a guidewire receiving lumen extending the length of the catheter shaft from a guidewire port in the proximal end of the shaft. Rapid exchange balloon catheters for similar procedures generally include a short guidewire lumen extending to the distal end of the shaft from a guidewire port located distal to the proximal end of the shaft.
In the case of a robust co-extruded catheter shaft, an inner layer can be comprised of a high modulus or high Shore D durometer nylon, preferably a Shore D durometer value greater than 80, such as Grilamid TR55 LX nylon 12 from EMS-American Grilon Inc., which provides a high modulus for enhanced pushability. Also, it would be beneficial if the glass transition temperature of the high modulus polymer forming the inner layer is greater than 100° C., and more preferably greater than 120° C. However, the TR55 LX or other high modulus amorphous nylon has a greater tendency to kink and is susceptible to attack by solvents. To combat the kink propensity and to protect the catheter shaft from solvents, a thin outer layer of lower modulus material such as Pebax is formed over the TR55 LX inner layer to serve as a protective layer and to resist kinking of the shaft. The outer layer can be selected from semi-crystalline polyamide or more preferably from a copolyamide of lower durometer value such as Pebax 72 D, Pebax 63 D, and the like, where the Shore D durometer value is less than 76.
By incorporating an amorphous polyamide such as TR 55 LX as one layer, the dimensional stability is increased for as the shelf life of the catheter increases due to the higher glass transition temperature, as compared with nylon 12 or Pebax which has a glass transition temperature at or below 55° C. Also, a higher tensile strength (approximately 11,000 psi) of amorphous nylon TR 55 LX compared with nylon 12 or Pebax (7,500-8,200) provides a higher rupture limit with the same wall thickness.
The co-axial tubing can be formed into a tapered configuration, where the radius of the shaft gradually reduces until the balloon attachment point. This gradual reduction in the radial component of the shaft serves to eliminate the mid-shaft portion of the catheter, which simplifies the manufacturing process by avoiding a laser operation or other mechanism to attach the mid-shaft.
In angioplasty balloons, an object is to apply a high pressure to the interior wall of the lumen to compress the plaque and/or to fully expand the stent. This relies on a robust balloon with a sturdy out wall and a high pressure capability. The compliance of the balloon, i.e., the expansion of the balloon as a function of internal pressure, is preferably low or flat to more accurately control the amount of pressure applied to the arterial wall. However, the deliverability of the balloon is also a factor, especially where tortuous body lumens are involved. Stiff balloons (i.e., high modulus materials) tend to have poor flexibility and lack the maneuverability to navigate the various body lumens, and thus make poor choices for catheter balloons. Conversely, flexible balloons (low modulus materials) that have high compliance are poorly suited to apply a precise known pressure on the arterial wall due to a high expansion rate per applied pressure. The goal is thus to increase the rupture strength by adding the high modulus material such as nylon to the softer polyamide material.
Soft polyamide materials such as Pebax™ are semi-crystalline polymers and usually include an amorphous segment. The amorphous segment has a lower density than the crystalline structure and thus is weaker in general than crystalline segments. If the amorphous segment can be reinforced by adding a small amount of a higher modulus material the response of the amorphous segment can be delayed and the overall strength of the material can be strengthened. The high modulus material preferably has a Shore D durometer hardness of 78 D or more. Suitable materials include transparent amorphous nylon such as nylon 12, and more preferably a nylon 12 with a aliphatic segment, an aromatic segment, or a cycloaliphatic segment. These nylons are transparent amorphous because they are essentially amorphous, lacking the crystalline structure of other more conventional nylon 12. The aliphatic segment, aromatic segment, or cycloaliphatic segment does not crystallize with the main chain, disrupting the formation of longer crystalline chains in the polymer. The amorphous segment of the transparent amorphous nylon 12 combines with the amorphous segment of the Pebax to strengthen the Pebax by enhancing the weakest link in the chain, thereby increasing the overall strength of the polymer.
In the embodiment illustrated in
Non-compliant or low-compliant balloon 14 and/or the shaft 11 is formed of a blend of a first polyamide having a Shore D durometer hardness greater than 78 D and a copolyamide of lower durometer hardness, preferably less than 76 D. A preferred polyamide having a Shore D durometer hardness greater than 78 D is an amorphous polyamide such as EMS TR 55 (transparent amorphous nylon 12), Arkema Rilsan G110 (transparent amorphous nylon 12), or Cristamid MS 110 (transparent amorphous nylon 12). The polyamide is preferably includes a cycloaliphatic segment, an aromatic segment, or an aliphatic segment. Such polyamides are also referred to as transparent polyamide. The preferred copolyamide material for forming the polymeric blend for the balloon is Pebax, and more preferably Pebax 72 D, Pebax 70 D, Pebax 63 D, or Pebax 55 D. Alternatively, the copolyamide of lower durometer hardness is preferably a block copolymer of nylon 12 and polytetramethylene oxide.
The flexural modulus of the polyamide is preferably greater than 1700 MPa (240,000 psi) and the flexural modulus of the copolyamide is less than 850 MPa (120,000 psi). The tensile strength at break of both polyamides is at least 50 MPa, and elongation at break of both polyamides is at least 150%.
The catheter shaft will generally have the dimensions of conventional dilatation or stent deploying catheters. The length of the catheter 10 may be about 90 cm to about 150 cm, and is typically about 135 cm. The outer tubular member 19 has a length of about 25 cm to about 40 cm, an outer diameter (OD) of about 0.039 in to about 0.042 in, and an inner diameter (ID) of about 0.032 in. The inner tubular member 20 has a length of about 25 cm to about 40 cm, an OD of about 0.024 in and an ID of about 0.018 in. The inner and outer tubular members may taper in the distal section to a smaller OD or ID.
The length of the compliant balloon 14 may be about 1 cm to about 4 cm, preferably about 0.8 cm to about 4.0 cm, and is typically about 2.0 cm. In an expanded state, at nominal pressure of about 8 to about 10 atm, the balloon diameter is generally about 0.06 in (1.5 mm) to about 0.20 in (5.0 mm). and the wall thickness is about 0.0006 in (0.015 mm) to about 0.001 in (0.025 mm), or a dual wall thickness of about 0.025 mm to about 0.056 mm. The burst pressure is typically about 20 to 26 atm, and the rated burst pressure is typically about 18 atm.
In a presently preferred embodiment, the balloon 14 may include wings, which may be folded into a low profile configuration (not shown) for introduction into and advancement within the patient's vasculature. When inflating the balloon to dilate a stenosis, the catheter 10 is inserted into a patient's vasculature to the desired location, and inflation fluid is delivered through the inflation lumen 21 to the balloon 14 through the inflation port 24. The semi-compliant or noncompliant balloon 14 expands in a controlled fashion with limited radial expansion, to increase the size of the passageway through the stenosed region. Similarly, the balloon has low axial growth during inflation, to a rated burst pressure of about 14 atm, of about 5 to about 10%. The balloon is then deflated to allow the catheter to be withdrawn. The balloon may be used to deliver a stent (not shown), which may be any of a variety of stent materials and forms designed to be implanted by an expanding member, see for example U.S. Pat. No. 5,514,154 (Lau et al.) and U.S. Pat. No. 5,443,500 (Sigwart), incorporated herein in their entireties by reference.
A proximal shaft for the over-the-wire catheter may have a tapered tubing coextruded and tapered with TR55 inner layer and Pebax 72 D outer layer. The proximal wall thickness of TR55 may be approximately 0.005″ and a proximal wall thickness of Pebax 72 D may be approximately 0.001″. A distal wall thickness of TR55 is approximately 0.002″ and a distal wall thickness of Pebax 72 D is approximately 0.001″. In addition to balloons, the blended composition has usefulness as other parts of the catheter, such as the guidewire enclosure 20 of
The polyamide having Shore D durometer greater than 78 D is preferably amorphous polyamide selected from polyamide such as EMS TR 55 (transparent amorphous nylon 12), Arkema Rilsan G110 (transparent amorphous nylon 12), or Cristamid MS 110 (transparent amorphous nylon 12). This polyamide is preferably a copolyamide comprising cycloaliphatic, and/or aromatic, and/or aliphatic segment. The other copolyamide of lower durometer is preferably a block copolymer of nylon 12 and polytetramethylene oxide, such as Pebax 72 D, Pebax 70 D or Pebax 63 D.
The high durometer polymer serves to increase resistance to collapse of the tubing and provides enhanced pushability while the lower durometer polymer provides flexibility and kink resistance. Although it is preferred to have blends of high miscibility, the blend ratio is such that the lower durometer polymer forms a “virtual” continuous phase while the higher durometer polymer forms “virtual” reinforcement.
As shown in
The shaft of
Various embodiments are described above in effort to illustrate the concepts of the present invention, but these embodiments are not intended to be limiting or exclusive. Rather, the scope of the invention is to be determined by the words of the appended claims, interpreted in the context of the above description but not limited to those examples and embodiments described above and shown in the Figures.
This application is a continuation of U.S. patent application Ser. No. 13/898,027, filed May 20, 2013, which is a continuation of U.S. patent application Ser. No. 12/478,929, filed Jun. 5, 2009, now U.S. Pat. No. 8,444,608, which is continuation-in-part of U.S. patent application Ser. No. 12/324,425 entitled “Low Compliant Catheter Tubing” filed Nov. 26, 2008, now U.S. Pat. No. 8,070,719, the contents each of which are incorporated by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4425919 | Alston et al. | Jan 1984 | A |
4563181 | Wijayarathna et al. | Jan 1986 | A |
4596563 | Pande | Jun 1986 | A |
4775371 | Mueller, Jr. | Oct 1988 | A |
4820349 | Saab | Apr 1989 | A |
4877031 | Conway et al. | Oct 1989 | A |
4886506 | Lovgren et al. | Dec 1989 | A |
4892519 | Songer et al. | Jan 1990 | A |
4952357 | Euteneuer | Aug 1990 | A |
4955895 | Sugiyama et al. | Sep 1990 | A |
4960410 | Pinchuk | Oct 1990 | A |
4976720 | Machold et al. | Dec 1990 | A |
4994047 | Walker et al. | Feb 1991 | A |
5047045 | Arney et al. | Sep 1991 | A |
5061273 | Yock | Oct 1991 | A |
5078702 | Pomeranz | Jan 1992 | A |
5085649 | Flynn et al. | Feb 1992 | A |
5112304 | Barlow et al. | May 1992 | A |
5156594 | Keith | Oct 1992 | A |
5176661 | Evard et al. | Jan 1993 | A |
5195969 | Wang et al. | Mar 1993 | A |
5205822 | Johnson et al. | Apr 1993 | A |
5207700 | Euteneuer | May 1993 | A |
5217434 | Arney | Jun 1993 | A |
5217482 | Keith | Jun 1993 | A |
5250059 | Andreas et al. | Oct 1993 | A |
5270086 | Hamlin | Dec 1993 | A |
5277199 | DuBois et al. | Jan 1994 | A |
5290232 | Johnson et al. | Mar 1994 | A |
5290306 | Trotta et al. | Mar 1994 | A |
5300025 | Wantink | Apr 1994 | A |
5304134 | Kraus et al. | Apr 1994 | A |
5312430 | Rosenbluth et al. | May 1994 | A |
5318032 | Lonsbury et al. | Jun 1994 | A |
5318526 | Cohen | Jun 1994 | A |
5334146 | Ozasa | Aug 1994 | A |
5342386 | Trotta | Aug 1994 | A |
5358486 | Saab | Oct 1994 | A |
5364357 | Aase | Nov 1994 | A |
5370616 | Keith et al. | Dec 1994 | A |
5378238 | Peters et al. | Jan 1995 | A |
5395336 | Barclay et al. | Mar 1995 | A |
5425712 | Goodin | Jun 1995 | A |
5447497 | Sogard et al. | Sep 1995 | A |
5451233 | Yock | Sep 1995 | A |
5454789 | Burns et al. | Oct 1995 | A |
5470315 | Adams | Nov 1995 | A |
5476477 | Bums | Dec 1995 | A |
5478320 | Trotta | Dec 1995 | A |
5484409 | Atkinson et al. | Jan 1996 | A |
5490837 | Blaeser et al. | Feb 1996 | A |
5496275 | Sirhan et al. | Mar 1996 | A |
5499980 | Euteneuer | Mar 1996 | A |
5507766 | Kugo et al. | Apr 1996 | A |
5512051 | Wang et al. | Apr 1996 | A |
5526823 | Wheeler | Jun 1996 | A |
5538510 | Fontirroche et al. | Jul 1996 | A |
5538513 | Okajima | Jul 1996 | A |
5545134 | Hilaire et al. | Aug 1996 | A |
5549552 | Peters et al. | Aug 1996 | A |
5554121 | Ainsworth et al. | Sep 1996 | A |
5556383 | Wang et al. | Sep 1996 | A |
5569195 | Saab | Oct 1996 | A |
5587125 | Roychowdhury | Dec 1996 | A |
5599326 | Carter | Feb 1997 | A |
5613979 | Trotta et al. | Mar 1997 | A |
5620649 | Trotta | Apr 1997 | A |
5622665 | Wang | Apr 1997 | A |
5632760 | Sheiban et al. | May 1997 | A |
5643209 | Fugoso et al. | Jul 1997 | A |
5658264 | Samson | Aug 1997 | A |
5690613 | Verbeek | Nov 1997 | A |
5728063 | Preissman et al. | Mar 1998 | A |
5743874 | Fischell et al. | Apr 1998 | A |
5743875 | Sirhan et al. | Apr 1998 | A |
5749849 | Engelson et al. | May 1998 | A |
5755690 | Saab | May 1998 | A |
5759173 | Preissman et al. | Jun 1998 | A |
5766151 | Valley et al. | Jun 1998 | A |
5769817 | Burgmeier | Jun 1998 | A |
5769819 | Schwab et al. | Jun 1998 | A |
5775327 | Randolph et al. | Jul 1998 | A |
5779731 | Leavitt | Jul 1998 | A |
5782811 | Samson et al. | Jul 1998 | A |
5791036 | Goodin et al. | Aug 1998 | A |
5792124 | Horrigan et al. | Aug 1998 | A |
5792144 | Fischell et al. | Aug 1998 | A |
5795325 | Valley et al. | Aug 1998 | A |
5795341 | Samson | Aug 1998 | A |
5797887 | Rosen et al. | Aug 1998 | A |
5814016 | Valley et al. | Sep 1998 | A |
5820594 | Fontirroche et al. | Oct 1998 | A |
5833657 | Reinhardt et al. | Nov 1998 | A |
5853400 | Samson | Dec 1998 | A |
5879369 | Ishida | Mar 1999 | A |
5879499 | Corvi | Mar 1999 | A |
5902290 | Peacock et al. | May 1999 | A |
5908406 | Ostapchenko et al. | Jun 1999 | A |
5911715 | Berg et al. | Jun 1999 | A |
5916193 | Stevens et al. | Jun 1999 | A |
5947939 | Mortier et al. | Sep 1999 | A |
5964778 | Fugoso et al. | Oct 1999 | A |
5989218 | Wasicek | Nov 1999 | A |
6004289 | Saab | Dec 1999 | A |
6004339 | Wijay | Dec 1999 | A |
6010521 | Lee et al. | Jan 2000 | A |
6021340 | Randolph et al. | Feb 2000 | A |
6024693 | Schock et al. | Feb 2000 | A |
6024722 | Rau et al. | Feb 2000 | A |
6027510 | Alt | Feb 2000 | A |
6036670 | Wijeratne et al. | Mar 2000 | A |
6056719 | Mickley | May 2000 | A |
6059751 | Ostapchenko et al. | May 2000 | A |
6059770 | Peacock et al. | May 2000 | A |
6071266 | Kelley | Jun 2000 | A |
6086556 | Hamilton et al. | Jul 2000 | A |
6102890 | Stivland et al. | Aug 2000 | A |
6124007 | Wang et al. | Sep 2000 | A |
6132824 | Hamlin | Oct 2000 | A |
6136258 | Wang et al. | Oct 2000 | A |
6146356 | Wang et al. | Nov 2000 | A |
6165166 | Samuelson et al. | Dec 2000 | A |
6165195 | Wilson et al. | Dec 2000 | A |
6168588 | Wilson | Jan 2001 | B1 |
6171275 | Webster, Jr. et al. | Jan 2001 | B1 |
6171278 | Wang et al. | Jan 2001 | B1 |
6179810 | Wantink et al. | Jan 2001 | B1 |
6179856 | Barbere | Jan 2001 | B1 |
6193686 | Estrada et al. | Feb 2001 | B1 |
6197015 | Wilson | Mar 2001 | B1 |
6210396 | MacDonald et al. | Apr 2001 | B1 |
6217547 | Lee | Apr 2001 | B1 |
6217565 | Cohen | Apr 2001 | B1 |
6242063 | Ferrera et al. | Jun 2001 | B1 |
6245053 | Benjamin | Jun 2001 | B1 |
6251093 | Valley et al. | Jun 2001 | B1 |
6264683 | Stack et al. | Jul 2001 | B1 |
6265016 | Hostettler et al. | Jul 2001 | B1 |
6306097 | Park et al. | Oct 2001 | B1 |
6306124 | Jones et al. | Oct 2001 | B1 |
6308342 | Qi et al. | Oct 2001 | B1 |
6358227 | Ferrera et al. | Mar 2002 | B1 |
6364894 | Healy et al. | Apr 2002 | B1 |
6402720 | Miller et al. | Jun 2002 | B1 |
6416494 | Wilkins | Jul 2002 | B1 |
6482348 | Wang | Nov 2002 | B1 |
6495090 | Wilkins et al. | Dec 2002 | B1 |
6495127 | Wallace et al. | Dec 2002 | B1 |
6500148 | Pinchuk et al. | Dec 2002 | B1 |
6508784 | Shu | Jan 2003 | B1 |
6530938 | Lee et al. | Mar 2003 | B1 |
6548010 | Stivland et al. | Apr 2003 | B1 |
6575934 | Duchamp | Jun 2003 | B2 |
6575958 | Happ et al. | Jun 2003 | B1 |
6579259 | Stevens et al. | Jun 2003 | B2 |
6585687 | Shkolnik | Jul 2003 | B1 |
6585688 | Ferrera et al. | Jul 2003 | B2 |
6589207 | El-Nounou | Jul 2003 | B1 |
6589226 | Owens | Jul 2003 | B1 |
6591472 | Noone et al. | Jul 2003 | B1 |
6620127 | Lee et al. | Sep 2003 | B2 |
6620128 | Simhambhatla | Sep 2003 | B1 |
6626889 | Simpson et al. | Sep 2003 | B1 |
6629961 | Israelsson et al. | Oct 2003 | B1 |
6645422 | Jung, Jr. et al. | Nov 2003 | B2 |
6648854 | Patterson et al. | Nov 2003 | B1 |
6663614 | Carter et al. | Dec 2003 | B1 |
6673291 | Field et al. | Jan 2004 | B1 |
6673302 | Wang et al. | Jan 2004 | B2 |
6695809 | Lee | Feb 2004 | B1 |
6702802 | Hancock et al. | Mar 2004 | B1 |
6718211 | Smits et al. | Apr 2004 | B2 |
6733487 | Keith et al. | May 2004 | B2 |
6756094 | Wang et al. | Jun 2004 | B1 |
6777644 | Peacock et al. | Aug 2004 | B2 |
6793647 | Cryer | Sep 2004 | B1 |
6796958 | Chen et al. | Sep 2004 | B2 |
6796960 | Cioanta et al. | Sep 2004 | B2 |
6835189 | Musbach et al. | Dec 2004 | B2 |
6837890 | Chiudzinski | Jan 2005 | B1 |
6863678 | Lee et al. | Mar 2005 | B2 |
6875197 | Simhambhatia et al. | Apr 2005 | B1 |
6887219 | Wantink et al. | May 2005 | B2 |
6890395 | Simhambhatia | May 2005 | B2 |
6893456 | Lumauig | May 2005 | B2 |
6911038 | Mertens et al. | Jun 2005 | B2 |
6913600 | Valley et al. | Jul 2005 | B2 |
6918920 | Wang et al. | Jul 2005 | B1 |
6946092 | Bertolino et al. | Sep 2005 | B1 |
6951555 | Suresh | Oct 2005 | B1 |
6951675 | Chin et al. | Oct 2005 | B2 |
6979342 | Lee et al. | Dec 2005 | B2 |
7026026 | Ferrera et al. | Apr 2006 | B2 |
7029732 | Wang et al. | Apr 2006 | B2 |
7037291 | Lee et al. | May 2006 | B2 |
7037295 | Tiernan et al. | May 2006 | B2 |
7074206 | Lee et al. | Jul 2006 | B2 |
7108877 | Blair et al. | Sep 2006 | B2 |
7112357 | Miller et al. | Sep 2006 | B2 |
7141059 | Duchamp et al. | Nov 2006 | B2 |
7147817 | Lim et al. | Dec 2006 | B1 |
7163523 | Devens, Jr. et al. | Jan 2007 | B2 |
7195638 | Sridharan | Mar 2007 | B1 |
7273485 | Simpson et al. | Sep 2007 | B2 |
7335185 | Tang et al. | Feb 2008 | B2 |
7341571 | Harris et al. | Mar 2008 | B1 |
7556634 | Lee et al. | Jul 2009 | B2 |
7662130 | Lee et al. | Feb 2010 | B2 |
7828766 | Durcan | Nov 2010 | B2 |
7833193 | Lee et al. | Nov 2010 | B2 |
7906066 | Wilson et al. | Mar 2011 | B2 |
7947059 | Chin et al. | May 2011 | B2 |
8012300 | Simpson et al. | Sep 2011 | B2 |
8052638 | Lee et al. | Nov 2011 | B2 |
8070719 | Lee et al. | Dec 2011 | B2 |
8382738 | Simpson et al. | Feb 2013 | B2 |
8388602 | Simpson et al. | Mar 2013 | B2 |
8403885 | Arana et al. | Mar 2013 | B2 |
8444608 | Haslinger et al. | May 2013 | B2 |
8613722 | Lee et al. | Dec 2013 | B2 |
8657782 | Arana et al. | Feb 2014 | B2 |
8721624 | Wilson et al. | May 2014 | B2 |
9023174 | Simpson et al. | May 2015 | B2 |
9056190 | Simpson et al. | Jun 2015 | B2 |
9205223 | Wilson et al. | Dec 2015 | B2 |
9216274 | Arana et al. | Dec 2015 | B2 |
9381325 | Haslinger et al. | Jul 2016 | B2 |
20010001812 | Valley et al. | May 2001 | A1 |
20010016702 | Benjamin | Aug 2001 | A1 |
20010029362 | Sirhan et al. | Oct 2001 | A1 |
20010037085 | Keith et al. | Nov 2001 | A1 |
20020018866 | Lee et al. | Feb 2002 | A1 |
20020072755 | Bigus et al. | Jun 2002 | A1 |
20020082637 | Lumauig | Jun 2002 | A1 |
20020165523 | Chin et al. | Nov 2002 | A1 |
20030009151 | Wang | Jan 2003 | A1 |
20030028234 | Miller et al. | Feb 2003 | A1 |
20030032920 | Wantink | Feb 2003 | A1 |
20030055447 | Lee et al. | Mar 2003 | A1 |
20030064130 | Blair et al. | Apr 2003 | A1 |
20030105426 | Jorgensen | Jun 2003 | A1 |
20030125712 | Zhou | Jul 2003 | A1 |
20030139762 | Lee | Jul 2003 | A1 |
20040059291 | McDonnell et al. | Mar 2004 | A1 |
20040059292 | Hisamatsu et al. | Mar 2004 | A1 |
20040064130 | Carter | Apr 2004 | A1 |
20040068240 | Goodin et al. | Apr 2004 | A1 |
20040087901 | Rice et al. | May 2004 | A1 |
20040097892 | Evans et al. | May 2004 | A1 |
20040131808 | Schoenie et al. | Jul 2004 | A1 |
20040167441 | Reynolds et al. | Aug 2004 | A1 |
20040170782 | Wang et al. | Sep 2004 | A1 |
20040173935 | Lim et al. | Sep 2004 | A1 |
20040181206 | Chiu et al. | Sep 2004 | A1 |
20040191443 | Hamlin | Sep 2004 | A1 |
20040215141 | Clarke et al. | Oct 2004 | A1 |
20040267195 | Currlin | Dec 2004 | A1 |
20040267280 | Nishide et al. | Dec 2004 | A1 |
20050015048 | Chiu et al. | Jan 2005 | A1 |
20050043679 | Devens et al. | Feb 2005 | A1 |
20050124976 | Devens et al. | Jun 2005 | A1 |
20050131445 | Holman et al. | Jun 2005 | A1 |
20050148997 | Valley et al. | Jul 2005 | A1 |
20050154414 | Perreault et al. | Jul 2005 | A1 |
20050186370 | Hamilton et al. | Aug 2005 | A1 |
20050228429 | Burgmeier et al. | Oct 2005 | A1 |
20050238833 | Wang et al. | Oct 2005 | A1 |
20050277878 | Lee | Dec 2005 | A1 |
20060008606 | Horn et al. | Jan 2006 | A1 |
20060136032 | Legarda et al. | Jun 2006 | A1 |
20060165926 | Weber | Jul 2006 | A1 |
20060175739 | Hession et al. | Aug 2006 | A1 |
20060282041 | Melsheimer et al. | Dec 2006 | A1 |
20070060863 | Goeken et al. | Mar 2007 | A1 |
20070142771 | Durcan | Jun 2007 | A1 |
20070167973 | Stupecky et al. | Jul 2007 | A1 |
20070191813 | Chen | Aug 2007 | A1 |
20070240817 | Strong et al. | Oct 2007 | A1 |
20070260177 | Warnack | Nov 2007 | A1 |
20070276426 | Euteneuer | Nov 2007 | A1 |
20080015540 | Muni et al. | Jan 2008 | A1 |
20080045895 | Simpson et al. | Feb 2008 | A1 |
20080045928 | Simpson et al. | Feb 2008 | A1 |
20080065188 | Pallazza | Mar 2008 | A1 |
20080077085 | Eidenschink et al. | Mar 2008 | A1 |
20080221550 | Lee | Sep 2008 | A1 |
20080262470 | Lee et al. | Oct 2008 | A1 |
20090005754 | Soetermans | Jan 2009 | A1 |
20090156998 | Arana et al. | Jun 2009 | A1 |
20090247946 | Lee et al. | Oct 2009 | A1 |
20090264822 | Johnson | Oct 2009 | A1 |
20100010439 | Burgmeier et al. | Jan 2010 | A1 |
20100130925 | Haslinger et al. | May 2010 | A1 |
20110315301 | Simpson et al. | Dec 2011 | A1 |
20120065586 | Lee et al. | Mar 2012 | A1 |
20120143129 | Simpson et al. | Jun 2012 | A1 |
20120296273 | Arana et al. | Nov 2012 | A1 |
20130160932 | Simpson et al. | Jun 2013 | A1 |
20130178795 | Wilson et al. | Jul 2013 | A1 |
20130253425 | Haslinger et al. | Sep 2013 | A1 |
20140081310 | Lee et al. | Mar 2014 | A1 |
20140163466 | Arana et al. | Jun 2014 | A1 |
20140213967 | Wilson et al. | Jul 2014 | A1 |
20150238737 | Simpson et al. | Aug 2015 | A1 |
20160074636 | Arana et al. | Mar 2016 | A1 |
Number | Date | Country |
---|---|---|
0 277 368 | Aug 1988 | EP |
0 414 350 | Feb 1991 | EP |
0 420 488 | Mar 1991 | EP |
0 737 487 | Oct 1996 | EP |
0 821 979 | Feb 1998 | EP |
0 904 795 | Mar 1999 | EP |
0 931 558 | Jul 1999 | EP |
0 962 227 | Dec 1999 | EP |
1 103 280 | May 2001 | EP |
1 287 846 | Mar 2003 | EP |
10-290837 | Nov 1998 | JP |
2001-018290 | Jan 2001 | JP |
2001-353225 | Dec 2001 | JP |
2005-167638 | Jun 2005 | JP |
WO 8902763 | Apr 1989 | WO |
WO 9320882 | Oct 1993 | WO |
WO 9518647 | Jul 1995 | WO |
WO 9603175 | Feb 1996 | WO |
WO 9634646 | Nov 1996 | WO |
WO 9726027 | Jul 1997 | WO |
WO 9913924 | Mar 1999 | WO |
WO 0134240 | May 2001 | WO |
WO 0151115 | Jul 2001 | WO |
WO 0189621 | Nov 2001 | WO |
WO 0236194 | May 2002 | WO |
WO 0236196 | May 2002 | WO |
WO 03004248 | Jan 2003 | WO |
WO 2005021083 | Mar 2005 | WO |
WO 2006126311 | Nov 2006 | WO |
WO 2007054364 | May 2007 | WO |
WO 2007146572 | Dec 2007 | WO |
WO 2010141765 | Dec 2010 | WO |
Entry |
---|
U.S. Appl. No. 09/957,526, Jun. 6, 2006 Certificate of Correction. |
U.S. Appl. No. 09/957,526, Jan. 24, 2005 Issue Fee payment. |
U.S. Appl. No. 09/957,526, Nov. 4, 2004 Notice of Allowance. |
U.S. Appl. No. 09/957,526, Sep. 21, 2004 Response to Non-Final Office Action. |
U.S. Appl. No. 09/957,526, Jul. 1, 2004 Non-Final Office Action. |
U.S. Appl. No. 09/957,526, Apr. 22, 2004 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 09/957,526, Feb. 17, 2004 Final Office Action. |
U.S. Appl. No. 09/957,526, Nov. 26, 2003 Response to Non-Final Office Action. |
U.S. Appl. No. 09/957,526, Jun. 23, 2003 Non-Final Office Action. |
U.S. Appl. No. 10/010,212, Mar. 6, 2006 Issue Fee payment. |
U.S. Appl. No. 10/010,212, Feb. 9, 2006 Notice of Allowance. |
U.S. Appl. No. 10/010,212, Dec. 27, 2005 Response to Final Office Action. |
U.S. Appl. No. 10/010,212, Oct. 19, 2005 Final Office Action. |
U.S. Appl. No. 10/010,212, Aug. 4, 2005 Response to Non-Final Office Action. |
U.S. Appl. No. 10/010,212, May 6, 2005 Non-Final Office Action. |
U.S. Appl. No. 10/010,212, Feb. 4, 2005 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 10/010,212, Dec. 2, 2004 Final Office Action. |
U.S. Appl. No. 10/010,212, Aug. 9, 2004 Response to Non-Final Office Action. |
U.S. Appl. No. 10/010,212, Jun. 16, 2004 Non-Final Office Action. |
U.S. Appl. No. 10/010,212, Mar. 22, 2004 Response to Non-Final Office Action. |
U.S. Appl. No. 10/010,212, Dec. 31, 2003 Non-Final Office Action. |
U.S. Appl. No. 10/010,212, Oct. 14, 2003 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 10/010,212, Jul. 7, 2003 Final Office Action. |
U.S. Appl. No. 10/010,212, Apr. 18, 2003 Response to Non-Final Office Action. |
U.S. Appl. No. 10/010,212, Jan. 15, 2003 Non-Final Office Action. |
U.S. Appl. No. 10/010,212, Dec. 17, 2002 Response to Restriction Requirement. |
U.S. Appl. No. 10/010,212, Nov. 25, 2002 Restriction Requirement. |
U.S. Appl. No. 10/392,697, Aug. 22, 2007 Issue Fee payment. |
U.S. Appl. No. 10/392,697, May 31, 2007 Notice of Allowance. |
U.S. Appl. No. 10/392,697, Feb. 26, 2007 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 10/392,697, Jan. 5, 2007 Final Office Action. |
U.S. Appl. No. 10/392,697, Sep. 29, 2006 Response to Non-Final Office Action. |
U.S. Appl. No. 10/392,697, Jul. 13, 2006 Non-Final Office Action. |
U.S. Appl. No. 10/392,697, May 1, 2006 Response to Restriction Requirement. |
U.S. Appl. No. 10/392,697, Mar. 27, 2006 Restriction Requirement. |
U.S. Appl. No. 11/038,971, May 29, 2009 Issue Fee payment. |
U.S. Appl. No. 11/038,971, Mar. 13, 2009 Notice of Allowance. |
U.S. Appl. No. 11/038,971, Sep. 19, 2008 Response to Non-Final Office Action. |
U.S. Appl. No. 11/038,971, Jul. 29, 2008 Non-Final Office Action. |
U.S. Appl. No. 11/038,971, Feb. 28, 2008 Response to Non-Final Office Action. |
U.S. Appl. No. 11/038,971, Nov. 28, 2007 Non-Final Office Action. |
U.S. Appl. No. 11/038,971, Sep. 18, 2007 Response to Non-Final Office Action. |
U.S. Appl. No. 11/038,971, Jun. 28, 2007 Non-Final Office Action. |
U.S. Appl. No. 11/038,971, Apr. 12, 2007 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 11/038,971, Feb. 16, 2007 Final Office Action. |
U.S. Appl. No. 11/038971, Nov. 13, 2006 Response to Non-Final Office Action. |
U.S. Appl. No. 11/038,971, Sep. 21, 2006 Non-Final Office Action. |
U.S. Appl. No. 11/196,134, Dec. 29, 2009 Issue Fee payment. |
U.S. Appl. No. 11/196,134, Sep. 30, 2009 Notice of Allowance. |
U.S. Appl. No. 11/196,134, Sep. 10, 2009 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 11/196,134, Jun. 10, 2009 Final Office Action. |
U.S. Appl. No. 11/196,134, Mar. 24, 2009 Response to Non-Final Office Action. |
U.S. Appl. No. 11/196,134, Dec. 24, 2008 Non-Final Office Action. |
U.S. Appl. No. 11/480,143, Feb. 3, 2011 Issue Fee payment. |
U.S. Appl. No. 11/480,143, Nov. 18, 2010 Notice of Allowance. |
U.S. Appl. No. 11/480,143, Aug. 23, 2010 Response to Non-Final Office Action. |
U.S. Appl. No. 11/480,143, Apr. 22, 2010 Non-Final Office Action. |
U.S. Appl. No. 11/480,143, Feb. 18, 2010 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 11/480,143, Feb. 4, 2010 Advisory Action. |
U.S. Appl. No. 11/480,143, Jan. 15, 2010 Response to Final Office Action. |
U.S. Appl. No. 11/480,143, Aug. 18, 2009 Final Office Action. |
U.S. Appl. No. 11/480,143, May 27, 2009 Response to Non-Final Office Action. |
U.S. Appl. No. 11/480,143, Jan. 27, 2009 Non-Final Office Action. |
U.S. Appl. No. 11/480,143, Oct. 28, 2008 Response to Restriction Requirement. |
U.S. Appl. No. 11/480,143, Oct. 17, 2008 Restriction Requirement. |
U.S. Appl. No. 11/763,623, Jan. 29, 2013 Issue Fee payment. |
U.S. Appl. No. 11/763,623, Oct. 29, 2012 Notice of Allowance. |
U.S. Appl. No. 11/763,623, Oct. 17, 2012 Applicant Initiated Interview Summary. |
U.S. Appl. No. 11/763,623, Oct. 21, 2010 Examiner Interview Summary. |
U.S. Appl. No. 11/763,623, Aug. 24, 2010 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 11/763,623, May 24, 2010 Notice of Appeal. |
U.S. Appl. No. 11/763,623, Feb. 23, 2010 Final Office Action. |
U.S. Appl. No. 11/763,623, Jan. 15, 2010 Response to Non-Final Office Action. |
U.S. Appl. No. 11/763,623, Oct. 15, 2009 Non-Final Office Action. |
U.S. Appl. No. 11/763,623, Jul. 20, 2009 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 11/763,623, Mar. 20, 2009 Final Office Action. |
U.S. Appl. No. 11/763,623, Mar. 3, 2009 Response to Non-Final Office Action. |
U.S. Appl. No. 11/763,623, Dec. 3, 2008 Non-Final Office Action. |
U.S. Appl. No. 11/763,623, Oct. 2, 2008 Response to Restriction Requirement. |
U.S. Appl. No. 11/763,623, Sep. 25, 2008 Restriction Requirement. |
U.S. Appl. No. 11/844,117, Aug. 2, 2011 Issue Fee payment. |
U.S. Appl. No. 11/844,117, Jun. 15, 2011 Notice of Allowance. |
U.S. Appl. No. 11/844,117, Mar. 23, 2011 Response to Non-Final Office Action. |
U.S. Appl. No. 11/844,117, Nov. 23, 2010 Non-Final Office Action. |
U.S. Appl. No. 11/844,117, Nov. 17, 2010 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 11/844,117, Aug. 17, 2010 Final Office Action. |
U.S. Appl. No. 11/844,117, Jun. 30, 2010 Response to Notice of Non-Compliant. |
U.S. Appl. No. 11/844,117, Jun. 23, 2010 Notice of Non-Compliant. |
U.S. Appl. No. 11/844,117, Jun. 17, 2010 Response to Non-Final Office Action. |
U.S. Appl. No. 11/844,117, Mar. 17, 2010 Non-Final Office Action. |
U.S. Appl. No. 11/844,117, Jan. 5, 2010 Response to Restriction Requirement. |
U.S. Appl. No. 11/844,117, Oct. 13, 2009 Restriction Requirement. |
U.S. Appl. No. 11/958,106, May 21, 2013 Certificate of Correction. |
U.S. Appl. No. 11/958,106, Feb. 20, 2013 Issue Fee payment. |
U.S. Appl. No. 11/958,106, Nov. 20, 2012 Notice of Allowance. |
U.S. Appl. No. 11/958,106, Oct. 23, 2012 Response to Non-Final Office Action. |
U.S. Appl. No. 11/958,106, Aug. 1, 2012 Non-Final Office Action. |
U.S. Appl. No. 11/958,106, May 29, 2012 Response to Notice of Non-Compliant. |
U.S. Appl. No. 11/958,106, May 17, 2012 Notice of non-Compliant. |
U.S. Appl. No. 11/958,106, May 7, 2012 Response to Non-Final Office Action. |
U.S. Appl. No. 11/958,106, Jan. 6, 2012 Non-Final Office Action. |
U.S. Appl. No. 11/958,106, Jun. 17, 2010 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 11/958,106, Mar. 17, 2010 Final Office Action. |
U.S. Appl. No. 11/958,106, Jan. 8, 2010 Response to Non-Final Office Action. |
U.S. Appl. No. 11/958,106, Jul. 8, 2009 Non-Final Office Action. |
U.S. Appl. No. 12/324,425, Oct. 31, 2011 Amendment after Notice of Allowance. |
U.S. Appl. No. 12/324,425, Sep. 22, 2011 Issue Fee payment. |
U.S. Appl. No. 12/324,425, Aug. 31, 2011 Notice of Allowance. |
U.S. Appl. No. 12/324,425, Jun. 6, 2011 Response to Non-Final Office Action. |
U.S. Appl. No. 12/324,425, Mar. 4, 2011 Non-Final Office Action. |
U.S. Appl. No. 12/477,695, Jun. 21, 2016 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 12/477,695, Apr. 21, 2016 Response after Final Office Action. |
U.S. Appl. No. 12/477,695, Jan. 21, 2016 Final Office Action. |
U.S. Appl. No. 12/477,695, May 16, 2014 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 12/477,695, Jul. 1, 2015 Non-Final Office Action. |
U.S. Appl. No. 12/477,695, Oct. 1, 2015 Response to Non-Final Office Action. |
U.S. Appl. No. 12/477,695, Jan. 16, 2014 Final Office Action. |
U.S. Appl. No. 12/477,695, Mar. 17, 2014 Response after Final Action. |
U.S. Appl. No. 12/477,695, Apr. 10, 2014 Applicant Initiated Interview Summary. |
U.S. Appl. No. 12/477,695, Sep. 20, 2013 Response to Non-Final Office Action. |
U.S. Appl. No. 12/477,695, Jun. 20, 2013 Non-Final Office Action. |
U.S. Appl. No. 12/477,695, Jan. 15, 2013 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 12/477,695, Oct. 24, 2012 Advisory Action. |
U.S. Appl. No. 12/477,695, Oct. 11, 2012 Response to Final Office Action. |
U.S. Appl. No. 12/477,695, Aug. 15, 2012 Final Office Action. |
U.S. Appl. No. 12/477,695, Apr. 16, 2012 Response to Non-Final Office Action. |
U.S. Appl. No. 12/477,695, Dec. 16, 2011 Non-Final Office Action. |
U.S. Appl. No. 12/478,929, Apr. 18, 2013 Issue Fee Payment. |
U.S. Appl. No. 12/478,929, Jan. 18, 2013 Notice of Allowance. |
U.S. Appl. No. 12/478,929, Sep. 24, 2012 Response to Non-Final Office Action. |
U.S. Appl. No. 12/478,929, Jun. 22, 2012 Non-Final Office Action. |
U.S. Appl. No. 12/478,929, Jul. 18, 2011 Request for Continued Examination (RCE). |
U.S. Appl. No. 12/478,929, Jun. 6, 2011 Response after Final Office Action. |
U.S. Appl. No. 12/478,929, Mar. 4, 2011 Final Office Action. |
U.S. Appl. No. 12/478,929, Dec. 9, 2010 Response to Non-Final Office Action. |
U.S. Appl. No. 12/478,929, Jul. 9, 2010 Non-Final Office Action. |
U.S. Appl. No. 12/479,700, Sep. 22, 2011 Issue Fee payment. |
U.S. Appl. No. 12/479,700, Aug. 22, 2011 Notice of Allowance. |
U.S. Appl. No. 12/479,700, May 20, 2011 Response to Non-Final Office Action. |
U.S. Appl. No. 12/479,700, May 13, 2011 Examiner Interview Summary. |
U.S. Appl. No. 12/479,700, Apr. 27, 2011 Response to Non-Final Office Action. |
U.S. Appl. No. 12/479,700, Oct. 27, 2010 Non-Final Office Action. |
U.S. Appl. No. 12/479,700, Oct. 14, 2010 Response to Restriction Requirement. |
U.S. Appl. No. 12/479,700, Oct. 4, 2010 Restriction Requirement. |
U.S. Appl. No. 12/687,265, Oct. 14, 2010 Issue Fee payment. |
U.S. Appl. No. 12/687,265, Aug. 5, 2010 Notice of Allowance. |
U.S. Appl. No. 13/224,917, Dec. 10, 2014 Response to Non-Final Office Action. |
U.S. Appl. No. 13/224,917, Mar. 2, 2015 Notice of Allowance. |
U.S. Appl. No. 13/224,917, Mar. 25, 2015 Issue Fee Payment. |
U.S. Appl. No. 13/224,917, Sep. 11, 2014 Non-Final Office Action. |
U.S. Appl. No. 13/224,917, Dec. 13, 2013 Response to Non-Final Office Action. |
U.S. Appl. No. 13/224,917, Sep. 12, 2013 Non-Final Office Action. |
U.S. Appl. No. 13/224,917, Aug. 23, 2013 Amendment and Request for Continued Examination (RCE). |
U.S. Appl. No. 13/224,917, May 28, 2013 Final Office Action. |
U.S. Appl. No. 13/224,917, Jan. 14, 2013 Response to Non-Final Office Action. |
U.S. Appl. No. 13/224,917, Oct. 12, 2012 Non-Final Office Action. |
U.S. Appl. No. 13/240,453, Nov. 19, 2013 Issue Fee payment. |
U.S. Appl. No. 13/240,453, Aug. 20, 2013 Notice of Allowance. |
U.S. Appl. No. 13/240,453, Apr. 30, 2013 Response to Non-Final Office Action. |
U.S. Appl. No. 13/240,453, Apr. 17, 2013 Applicant Initiated Interview Summary. |
U.S. Appl. No. 13/240,453, Dec. 5, 2012 Non-Final Office Action. |
U.S. Appl. No. 13/240,453, Nov. 1, 2012 Response to Restriction Requirement. |
U.S. Appl. No. 13/240,453, Oct. 2, 2012 Restriction Requirement. |
U.S. Appl. No. 13/398,178, Jan. 25, 2013 Issue Fee payment. |
U.S. Appl. No. 13/398,178, Oct. 25, 2012 Notice of Allowance. |
U.S. Appl. No. 13/398,178, Oct. 16, 2012 Preliminary Amendment. |
U.S. Appl. No. 13/562,810, Jan. 9, 2014 Issue Fee Payment. |
U.S. Appl. No. 13/562,810, Nov. 6, 2013 Notice of Allowance. |
U.S. Appl. No. 13/562,810, Oct. 8, 2013 Response to Non-Final Office Action. |
U.S. Appl. No. 13/562,810, Jul. 8, 2013 Non-Final Office Action. |
U.S. Appl. No. 13/775,659, Jan. 26, 2015 Response to Non-Final Office Action. |
U.S. Appl. No. 13/775,659, Feb. 17, 2015 Notice of Allowance. |
U.S. Appl. No. 13/775,659, May 12, 2015 Issue Fee Payment. |
U.S. Appl. No. 13/775,659, Oct. 24, 2014 Non-Final Office Action. |
U.S. Appl. No. 13/775,699, Mar. 31, 2014 Issue Fee Payment. |
U.S. Appl. No. 13/775,699, Dec. 31, 2013 Notice of Allowance. |
U.S. Appl. No. 13/775,699, Oct. 28, 2013 Response to Restriction Requirement. |
U.S. Appl. No. 13/775,699, Sep. 27, 2013 Restriction Requirement. |
U.S. Appl. No. 13/898,027, Jun. 8, 2016 Issue Fee Payment. |
U.S. Appl. No. 13/898,027, Mar. 21, 2016 Notice of Allowance. |
U.S. Appl. No. 14/083,821, Aug. 18, 2016 Restriction Requirement Filed. |
U.S. Appl. No. 14/180,550, Nov. 17, 2015 Issue Fee Payment. |
U.S. Appl. No. 14/180,550, Apr. 13, 2015 Response to Non-Final Office Action. |
U.S. Appl. No. 14/180,550, Aug. 17, 2015 Notice of Allowance. |
U.S. Appl. No. 14/180,550, Jan. 13, 2015 Non-Final Office Action. |
U.S. Appl. No. 14/230,581, Nov. 5, 2015 Issue Fee Payment. |
U.S. Appl. No. 14/230,581, Aug. 5, 2015 Notice of Allowance. |
U.S. Appl. No. 14/950,414, Sep. 14, 2016 Issue Fee Payment. |
U.S. Appl. No. 14/950,414, Jun. 15, 2016 Notice of Allowance. |
U.S. Appl. No. 14/950,414, May 6, 2016 Response to Non-Final Office Action. |
U.S. Appl. No. 14/950,414, Feb. 8, 2016 Non-Final Office Action. |
Cordis' Product Brochure; The Journey Inspires the Design, AQUA T3, Dec. 2002. |
The Manufacturing Process Section of the Phelps Dodge High Performance Conductors Brochure, a Primer on Polymide Tubing, p. 1. |
http://www.zeusinc.com/peek—resin.asp. |
www.sigmaaldrich.com/img/assets/3900/Thermal—Transitions—of—Homopolymers.pdf. |
Etherington & Roberts Dictionary, http://Palimpsest.stanford.edu/don/dt/dt1549.html. |
Polymers: Structure and Properties, C.A. Daniels, Ph.D., P.E.; Technomic Publishing Co., Inc. |
International Search Report for PCT/US2010/037313, dated Apr. 28, 2011. |
International Search Report for PCT/US2007/071873, dated Apr. 14, 2008. |
International Search Report for PCT/US2008/086270, dated Jun. 3, 2009. |
Number | Date | Country | |
---|---|---|---|
20160279300 A1 | Sep 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13898027 | May 2013 | US |
Child | 15176297 | US | |
Parent | 12478929 | Jun 2009 | US |
Child | 13898027 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 12324425 | Nov 2008 | US |
Child | 12478929 | US |